Genentech drug raises clot risk
From Times Wire Services
Genentech Inc.’s cancer drug Avastin, when given along with chemotherapy, raises the risk of blood clots, according to a company-sponsored study that confirms a hazard already associated with the drug.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
